www.feizichem.com    Shijiazhuang FeiZi Chemical Technology Co., Ltd. 

Following a ruling by the National Intellectual Property Administration, the crystalline-form patent for the blockbuster global drug sacubitril valsartan sodium tablets (trade name: Novartis Entresto) has been granted an extension of 1,826 days, extending its patent protection period to 2031. This news has not only brought relief to the original research and development company Novartis but has also stabilized the position of its key suppliers, including CDMO enterprises such as Jiuzhou Pharmaceutical. For fine chemical companies positioned upstream in the industrial chain, this development is not only a positive signal passed down from downstream customers but also serves as a profound validation of their own technological barriers and compliance capabilities. As a pillar enterprise within the Shijiazhuang Circular Chemical Industry Park, Shijiazhuang Feizi Chemical Co., Ltd. (hereinafter referred to as “Feizi Chemical”) is closely monitoring these market developments and, leveraging its deep-rooted expertise in high-complexity pharmaceutical intermediates, is preparing to further strengthen its supply-chain position during this extended "golden window" period.

The Supply-Chain Logic Behind Patent Extensions: A Steadfast Commitment to Shifting from “Quantity” to “Quality”

The extension of the NovoNorm patent period means that the originator drug and its authorized generic versions will continue to dominate the market over the next five years, placing even higher demands on the stability of supply for upstream active pharmaceutical ingredients and intermediates. For Feizi Chemical, this is not only a market signal but also a strategic opportunity. In the field of pharmaceutical intermediates—particularly in the synthesis of complex small-molecule drugs like Norsulto—high-purity, high-tech-demand nitrogen-containing heterocyclic compounds or specific fluorinated/chlorinated intermediates are often required. Feizi Chemical understands deeply that companies aspiring to join this top-tier supply chain must possess “irreplaceability.” Just as Jiuzhou Pharmaceutical has achieved growth by securing strong ties with major customers, Feizi Chemical is also building its own “moat” by focusing intently on niche segments.

Feizi Chemical’s “Invisible” Competitive Edge: Benchmarking Against High-End Pharmaceutical Intermediate Standards

Although the specific synthesis route for Noshintuo is a commercial trade secret, based on Feizi Chemical’s existing product and technology portfolio, the company possesses both the capability and potential to undertake such high-end orders.

Highly sophisticated synthesis capabilities for nitrogen-containing heterocycles: The core structure of Nusinersen involves complex pyrimidinone and biphenyl moieties. Feizi Chemical boasts a mature production line for nitrogen-containing heterocyclic derivatives such as piperazine and pyrazolone compounds. For instance, the company produces high-value-added intermediates like 1-(2,3-Dichlorophenyl)piperazine hydrochloride (CAS: 119532-26-2). The synthesis process for these compounds demands extremely stringent control over reaction conditions—this is precisely the technological edge that sets Feizi Chemical apart from ordinary chemical manufacturers.

Customized R&D (CRO/CMO) Response Speed: In response to market changes brought about by patent extensions, original research manufacturers and CDMOs often optimize processes to reduce costs. Leveraging the R&D resources of the Shijiazhuang Circular Chemical Industry Park, Feizi Chemical is able to swiftly meet customers’ customized demands for specific intermediates in new process routes—whether it’s a special reagent like Chromotropic acid disodium salt dihydrate (CAS: 5808-22-0) or other functional monomers—and can provide solutions that comply with GMP standards.

Long-termism in Responding to the “Patent Cliff”

Although Nohintuo has secured five years of “life extension” in the domestic market, competition from generic drugs remains fierce worldwide. This serves as a reminder to all supply-chain companies: relying solely on a single blockbuster product carries risks. Feizi Chemical’s strategy is “walking on multiple legs.” While consolidating its existing pharmaceutical intermediate business, the company is actively leveraging its versatile technology platform in the fine chemical sector to expand into the fields of electronic chemicals and new materials. This diversified product portfolio enables Feizi Chemical to maintain operational resilience even when faced with fluctuations in demand for a single downstream product.

Conclusion

The patent extension for Novartis’ Nucala represents a victory not only for innovative pharmaceutical companies but also for high-quality supply-chain partners. On the vibrant chemical industry hub of Shijiazhuang, Feizi Chemical is quietly supporting every breakthrough downstream with its rigorous processes and consistent quality. Over the next five years—and beyond—Feizi Chemical will continue to play its role as a “behind-the-scenes hero,” contributing to the safety and stability of China’s pharmaceutical industry chain.